Additional cytogenetic changes and previous genotoxic exposure predict unfavorable prognosis in myelodysplastic syndromes and acute myeloid leukemia with der(1;7)(q10;p10)

Cancer Genetics and Cytogenetics
Hui-Hua HsiaoK Ohyashiki

Abstract

We analyzed 23 patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) showing a der(1;7)(q10;p10) [hereafter der(1;7)] to identify the exact predictive factor of this cytogenetic change. Eight (34.8%) patients, including six with MDS and two with AML patients, had a previous history of genotoxic exposure, especially radiation and/or antimetabolites. Patients with der(1;7) consisted of three groups: one third of patients had a previous history of genotoxic agents, one third had additional cytogenetic changes at the time of MDS/AML diagnosis without previous exposure history, and the remaining one third had neither a previous exposure history nor additional cytogenetic changes. The current study demonstrated that the poor outcome of MDS/AML with der(1;7) is caused by the high frequency of associated risk factors (i.e., previous history of genotoxic exposure, the presence of additional cytogenetic changes, or both). Identification of prognostic disadvantage might be required for applying the appropriate strategy in managing MDS/AML patients with rare der(1;7) abnormality.

References

Jan 1, 1991·Genes, Chromosomes & Cancer·B JohanssonF Mitelman
Nov 1, 1985·Cancer Genetics and Cytogenetics·C MecucciH Van den Berghe
Nov 1, 1985·Cancer Genetics and Cytogenetics·J M ScheresP S Meltzer
Jul 21, 1998·Leukemia Research·C Mecucci
Dec 12, 2001·Critical Reviews in Oncology/hematology·P Mhawech, A Saleem
Sep 20, 2002·Blood·James W VardimanRichard D Brunning

❮ Previous
Next ❯

Citations

Mar 10, 2008·Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine·Kazuma Ooyashiki
Nov 27, 2007·Cancer Genetics and Cytogenetics·Tae Sung ParkJong Rak Choi
Sep 15, 2007·Cancer Genetics and Cytogenetics·Sheila N J SaitMaria R Baer
Jan 11, 2007·Cancer Genetics and Cytogenetics·Omar Ferkad Faraj OdishKazuma Ohyashiki
Nov 1, 2006·Cancer Genetics and Cytogenetics·Yi-Chang LiuKazuma Ohyashiki
Feb 13, 2008·Acta Haematologica·Nadja Kokalj VokacPeter Cernelc

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.